Introduction
============

Pain is a common cause of disability in older adults.[@b1-jpr-9-1131]--[@b6-jpr-9-1131] Among its consequences are risk of future fall injuries,[@b7-jpr-9-1131] reduced life satisfaction and quality of life, increased mood disturbances, impairments in activities of daily living, and increased health care utilization and costs.[@b2-jpr-9-1131],[@b4-jpr-9-1131],[@b8-jpr-9-1131]--[@b10-jpr-9-1131] Previous studies on pain in older adults have reported prevalence from 24% to 72%,[@b1-jpr-9-1131],[@b10-jpr-9-1131]--[@b14-jpr-9-1131] a variability that may be due to methodological dissimilarities, case definitions, and cultural differences across studies.[@b9-jpr-9-1131],[@b11-jpr-9-1131],[@b15-jpr-9-1131],[@b16-jpr-9-1131] While it is broadly accepted that pain prevalence is higher in the elderly than in younger ages,[@b17-jpr-9-1131],[@b18-jpr-9-1131] a recent review argues that a general estimation of pain prevalence in the elderly is not feasible.[@b19-jpr-9-1131] Hence, there is a need for epidemiological studies to investigate the prevalence of pain in the elderly.

On the other hand, pain intensity, pain frequency, and the extent of spreading of pain on the body (i.e., the spatial distribution) influence the impact and the consequences of pain.[@b12-jpr-9-1131],[@b20-jpr-9-1131]--[@b28-jpr-9-1131] Widespread pain (WSP), in particular, is associated with lower levels of quality of life,[@b28-jpr-9-1131] decreased functionality and work status,[@b29-jpr-9-1131],[@b30-jpr-9-1131] and greater future disability.[@b30-jpr-9-1131] However, recent evidence suggests that not only WSP but also conditions with more limited pain spread can promote significant disabilities in the elderly.[@b24-jpr-9-1131] In fact, the majority of patients with pain cannot be classified into the WSP subgroup, and in order to cover the whole spectrum of "widespreadness", some studies have used the number of pain sites based on a body manikin.[@b30-jpr-9-1131] As pointed out by Grimby-Ekman et al,[@b24-jpr-9-1131] identifying the number of painful sites may have advantages in epidemiological studies but lacks validity in a clinical setting. Spatial categories of pain used clinically are local pain (LP), regional pain (RP), and WSP.[@b31-jpr-9-1131],[@b32-jpr-9-1131] A recent epidemiological study found that the vast majority of patients with pain had a regional pain condition; the study also suggested that future analyses should split this group into two categories, an approach used by a large study from the United Kingdom.[@b33-jpr-9-1131] Few studies have investigated the prevalence of pain spread categories in the elderly, and even fewer studies have performed in-depth analyses of the associations of pain spread.[@b1-jpr-9-1131],[@b10-jpr-9-1131],[@b15-jpr-9-1131],[@b16-jpr-9-1131],[@b34-jpr-9-1131],[@b35-jpr-9-1131]

The link between pain and sex is unambiguous; women demonstrate higher prevalence of pain than men.[@b1-jpr-9-1131],[@b12-jpr-9-1131],[@b29-jpr-9-1131],[@b36-jpr-9-1131]--[@b38-jpr-9-1131] However, the relationship between age and pain remains controversial; some studies demonstrate that pain prevalence decreases with age, while others support an opposing association.[@b10-jpr-9-1131],[@b12-jpr-9-1131],[@b34-jpr-9-1131] Some others, though, suggest that there is no concrete association between pain and age.[@b1-jpr-9-1131],[@b39-jpr-9-1131] Furthermore, several studies indicate that pain, especially WSP, is associated with increased prevalence of psychological comorbidities (e.g., depression and anxiety) as well as somatic conditions (e.g., cardiovascular disorders \[CVDs\], hypertension, and diabetes).[@b33-jpr-9-1131],[@b40-jpr-9-1131]--[@b42-jpr-9-1131] It is not known if such conditions are comorbidities to pain, including different pain categories, also in the elderly. Pain and possible comorbidities in older adults are often associated with medications and lifestyle factors such as nicotine, alcohol intake, and physical activity, factors that are usually not addressed in the epidemiological studies.[@b1-jpr-9-1131],[@b34-jpr-9-1131]

Awareness of the spreading of pain on the body in older adults is crucial for clinical evaluation and for pain prevention and management. To this end, this study aimed to estimate the prevalence of different pain categories based on the pain spread on the body and to analyze how sex, age, comorbidities, medications, nicotine, alcohol intake, and physical activity are associated with these pain categories.

Methods
=======

Throughout this article, the terms older adults and/or elderly will refer to individuals who are ≥65 years old.[@b43-jpr-9-1131]

Subjects and procedure
----------------------

This cross-sectional study collected data from a sampling frame based on the Swedish Total Population Register (STPR) for the two largest cities (Linköping and Norrköping) of Östergötland County, located in southeastern Sweden. The STPR consists of \~49320 older adults. From this registry, a stratified sample of 2000 subjects was randomly selected based on five age strata (65--69 years, 70--74 years, 75--79 years, 80--84 years, and 85 years and older). This procedure resulted in a total sample of 10000 eligible subjects.[@b8-jpr-9-1131] A postal survey was conducted in October 2012 followed by up to two postal reminders (at 2-week intervals). The collection of surveys closed in January 2013. Data were collected by Statistics Sweden (SCB). The study was approved by the Regional Ethics Research Committee in Linköping, Sweden (Dnr: 2012/154-31). Completion of postal survey was deemed to be agreement of patient informed consent.

Assessments
-----------

### Pain categories based on spreading of pain on the body

The subjects marked the site of their pain on a body manikin divided into a total of 45 sections on the front and on the back.[@b24-jpr-9-1131] Based on these 45 sections, 23 anatomical regions were determined and a total pain index score, ranging from 0 to 23, was calculated. Using a slightly modified definition developed by MacFarlane et al,[@b44-jpr-9-1131] we defined WSP as pain in at least two sections in two contralateral limbs and the axial skeleton that were equally marked on the front and the back of the manikin. MacFarlane et al[@b44-jpr-9-1131] defined WSP in limbs to be present "if there are at least two painful sections (in two contralateral limbs)", a definition that does not require pain to be marked equally on the front and back of the manikin. Therefore, our study employs a more rigorous definition of WSP than the American College of Rheumatology (ACR) criteria.[@b45-jpr-9-1131]

In addition to WSP, we defined the following pain categories: 1) no pain (NP) if the participants reported zero anatomical sites with pain (i.e., pain index = 0) -- zero duration of pain in months and zero pain intensity (this group serves as a control group); 2) LP if the participants reported 1--2 anatomical sites with pain; 3) regional pain medium (RP-Medium) if the participants reported 3--6 anatomical sites with pain; and 4) regional pain heavy (RP-Heavy) if the participants reported 7--17 anatomical pain sites with pain but not fulfilling the WSP criteria. WSP -- a common clinical entity -- depends both on the number of pain sites and on their spatial distribution. A minority of subjects with RP-Heavy could have a higher number of pain sites than some of the subjects with WSP[@b24-jpr-9-1131]; however, the 95% confidence intervals for the number of pain sites clearly differed between RP-Heavy and WSP. Subsequently, we also captured the duration of pain in months. Respondents who reported subacute pain (i.e., pain \<3 months) were also included in the aforementioned pain categories. Additionally, we assessed the mean pain intensity using an eleven-point Numeric Rating Scale (NRS7d): 0 = no pain and 10 = worst imaginable pain.[@b46-jpr-9-1131]

Basic demographic data
----------------------

Sex and age were recorded from the respondents' answers in the postal survey.

Comorbidities
-------------

The evaluation of comorbidities was based on a 12-item self-reported questionnaire covering a wide range of common comorbidities as follows: 1) traumatic injuries; 2) rheumatoid arthritis and osteoarthritis; 3) CVDs (including hypertension and coronary artery diseases); 4) pulmonary disorders; 5) depressive disorders; 6) anxiety disorders; 7) gastrointestinal disorders; 8) disorders of the central nervous system (CNS), including ophthalmological and ear--nose--throat disorders; 9) urogenital disorders; 10) skin disorders; 11) tumors and cancer; and 12) metabolic disorders (including diabetes, obesity, anorexia, bulimia, and goiter).

These comorbidities were reported on a five-point scale: 1) No; 2) Yes, according to both my own and my doctor's opinions; 3) Yes, according to my own opinion; 4) Yes, according to my doctor's opinion; and 5) Do not know. We combined the answers from 2, 3, and 4 into the category "Yes" in order to have a robust measurement of the presence of a certain comorbidity vs the answer option "No". The answer option "Do not know" was recorded as missing.

Medications
-----------

The assessment of medications was divided into two parts. In the first part, the subjects were asked to report the prescribed medications they had taken during the previous 2 weeks: 1) analgesics; 2) gastroesophageal reflux medication; 3) constipation medication; 4) hypnotics; 5) anxiolytics; 6) antidepressants; 7) anti-inflammatory medication; 8) cardiovascular medication; 9) medication for peripheral vascular disorders; 10) medication for skin disorders; and 11) insulin. In the second part, we recorded the non-prescribed medications during the previous 2 weeks: 1) analgesics; 2) gastroesophageal reflux medication; 3) constipation medication; 4) anti-inflammatory medication; 5) medication for skin disorders; 6) asthma medication; 7) general improvement of vitality supplements; 8) nutrition deficiencies (including B, C, and D vitamins); and 9) herbal remedies used for specific complaints and health problems. Each item had three alternatives: "No", "Yes, occasionally", and "Yes, more or less every day". In the analyses, these items were dichotomized -- "Yes, more or less every day" vs the two other alternatives.

Nicotine and alcohol intake
---------------------------

From the instrument the Health Curve (*Hälsokurvan*), two questions were chosen concerning nicotine intake and frequency. The following questions were asked: 1) "Do you smoke?" and 2) "Do you use snuff?" The alternative answers were coded on a five-point scale: 1 = never and 5 = daily habit.[@b47-jpr-9-1131] For analytical purposes, we combined smoking and snuff habits into the category nicotine intake, and these answers were dichotomized as follows: "never" vs the four other alternatives. One question concerned alcohol intake: "Do you drink alcohol regularly?" The alternative answers were "Yes" and "No".

Physical activity
-----------------

Physical activity was measured with the Godin Leisure-Time Exercise Questionnaire (GLTEQ).[@b48-jpr-9-1131] The GLTEQ contains four questions where the respondents state how many times a week they participate in "strenuous", "moderate", and "mild" exercise. A total leisure activity score is calculated by the times per week stated for the different intensities multiplied by nine for strenuous, five for moderate, and three for mild. A high score indicates higher intensity and higher frequency of weekly leisure-time activities.[@b48-jpr-9-1131]

Data analysis
-------------

Data were analyzed using SPSS version 23.0 for Windows (IBM Corporation, Armonk, NY, USA). All tests were two-tailed and used a conventional threshold of *a*=0.05 for significance. All statistical analyses were weighted to account for unequal possibilities of sample selection by weighting cases regarding age strata, sex, and city. The sampling weights were calculated by Statistics Sweden (SCB). Descriptive statistics were used to present all the variables of interest. We presented mean ± standard deviation (SD) for continuous variables and n (%) for categorical variables. Analysis of variance, Student's unpaired *t*-test, and Fisher's exact test were used where appropriate.

Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) on the effects of sex and age, comorbidities, medications, nicotine, alcohol intake, and physical activity in each pain category vs no pain. To determine which variables should be entered into the full multivariate model, univariate logistic regression analyses were performed with each variable one at a time (single-predictor model). Only variables with *p*\<0.05 in the single-predictor model were included in the full multivariate model. We further examined problems of multicollinearity among the independent categorical variables using the phi coefficient (Φ). In the case of high correlation (Φ≥0.30)[@b49-jpr-9-1131] between pairs of variables, only one variable was entered into the full multivariate model. In all the regression models, however, we excluded the pain intensity, non-prescribed analgesics, as well as non-prescribed gastroesophageal reflux medication, constipation medication, anti-inflammatory medication, and medication for skin disorders due to the high correlation with the pain categories and these prescribed medications. The result of this procedure was examined by reanalyzing the multivariate model with all variables together (correlated variables and not) in one model; both analyses were compared. The goodness of fit of the full multivariate model was examined using the Hosmer--Lemeshow test.

Results
=======

Descriptive characteristics
---------------------------

The final sample consisted of 6611 respondents (response rate: 66.1%; 128 excluded because of missing data). The average age was 75.0 years (SD=7.7), and 3554 respondents (53.8%) were women. There was a predominance of nonsmokers/non-snuff users (84.9%) and alcohol users (72.0%). The mean score of physical activity was 21.5 (SD=20.9), and the mean pain intensity was 4.3 (SD=2.4) ([Table 1](#t1-jpr-9-1131){ref-type="table"}). The most common comorbidities were CVDs (53.8%), rheumatoid arthritis/osteoarthritis (37.0%), and disorders of the CNS (39.5%). The most common medications were prescribed cardiovascular medication (31.3%) and non-prescribed nutritional deficiency medications (21.3%) ([Table 2](#t2-jpr-9-1131){ref-type="table"}).

Prevalence of pain and distribution of pain categories
------------------------------------------------------

The overall fraction of pain was 51.3%. The criteria for the LP were met by 1585 respondents, a prevalence of 24.1% among all respondents. RP-Medium was reported by 1344 respondents, corresponding to a prevalence of 20.3%. RP-Heavy was reported by 341 respondents, corresponding to a prevalence of 5.2%. With a prevalence of 1.7%, 114 respondents met the criteria of the WSP ([Figure 1](#f1-jpr-9-1131){ref-type="fig"}). Women reported a higher prevalence of all pain categories compared to men (*p*\<0.001). Age distribution did not differ among the five pain categories (*p*=0.21). As expected, statistically significant differences were found among the pain categories with respect to pain intensity (*p*\<0.001) ([Table 1](#t1-jpr-9-1131){ref-type="table"}).

Lifestyle factors in the pain categories
----------------------------------------

Significant overall differences were found among the five pain categories with regard to alcohol intake and physical activity (both *p*\<0.001). Nicotine intake did not differ significantly among the pain categories ([Table 1](#t1-jpr-9-1131){ref-type="table"}).

Comorbidities and prescribed and non-prescribed medications in the pain categories
----------------------------------------------------------------------------------

Prominent and significant differences were found between the five pain categories and the percentages of the comorbidities and the medications (almost all *p*\<0.001) ([Table 2](#t2-jpr-9-1131){ref-type="table"}). Hence, in WSP, higher prevalence of comorbidities and medications was observed compared to the other categories with few exceptions ([Table 2](#t2-jpr-9-1131){ref-type="table"}).

Results of single-predictor analysis
------------------------------------

The single-predictor analysis is presented in [Table 3](#t3-jpr-9-1131){ref-type="table"}. As expected, spreading of pain was associated with women more strongly than with men (all *p*\<0.001). In respondents 75--79 years old, compared to those 65--69 years old, PR-Heavy was more common than in those without pain (*p*=0.02). All pain categories were positively associated with almost all comorbidities and medications. Nicotine intake was not associated with the pain categories. Alcohol intake was lower in the pain groups than in those without pain. Physical activity was negatively associated with all pain categories.

Results of multivariate analysis
--------------------------------

The results of the full multivariate model are presented in [Table 4](#t4-jpr-9-1131){ref-type="table"}. Being a woman was independently associated with RP-Medium, RP-Heavy, and WSP. RP-Heavy was less likely to occur in 80--84 year-olds and \>85 year-olds compared to 65--69 year-olds. Traumatic injuries, rheumatoid arthritis/osteoarthritis, and analgesics were positively associated with all pain categories. An association with gastrointestinal disorders was found in LP, RP-Medium, and RP-Heavy. Depressive disorders were positively associated with all pain categories, except for LP. Disorders of the CNS were positively associated with the RP-Heavy and WSP. Medication for peripheral vascular disorders was positively associated with RP-Medium, and hypnotics were positively associated with RP-Heavy.

Discussion
==========

This large-scale cross-sectional study demonstrated an illustrative depiction of the prevalence of pain categories based on pain spread and its relation to basic demographic characteristics, comorbidities, medication, and lifestyle factors in the elderly. The stratified age and the random sampling methodology implemented in this survey are an additional strength. We found a high overall prevalence of spreading of pain (both subacute and chronic); the highest prevalence was observed in LP and the lowest in WSP. Pain intensity was higher in WSP. Female sex had strong correlation with all pain categories, with the exception of LP. Numerous comorbidities and medications were associated with spreading of pain; however, only traumatic injuries, rheumatoid arthritis/osteoarthritis, and analgesics were related to all pain categories. Evidently, the ratios of these associations increased with the pain spread from LP to RP-Medium, RP-Heavy, or WSP.

We found that \>50% of older individuals report pain, a rate quite similar compared to the prevalence reported in some other studies of older adults.[@b1-jpr-9-1131],[@b12-jpr-9-1131],[@b14-jpr-9-1131] The highest, and also similar, prevalence was found for LP and RP-Medium, results that are partly consistent with earlier investigations based on spreading of pain.[@b24-jpr-9-1131],[@b31-jpr-9-1131],[@b40-jpr-9-1131] The observation of the remarkably lower prevalence of WSP relative to those reported by other studies[@b24-jpr-9-1131],[@b31-jpr-9-1131],[@b35-jpr-9-1131],[@b40-jpr-9-1131] was somehow unexpected. The Manchester definition of WSP may account for this variability. Indeed, studies using the Manchester criteria have found lower prevalence of WSP than studies using the American College of Rheumatology criteria.[@b15-jpr-9-1131],[@b24-jpr-9-1131],[@b31-jpr-9-1131],[@b40-jpr-9-1131],[@b45-jpr-9-1131] Environmental and genetic factors could also explain the discrepancies in the rate of WSP.[@b50-jpr-9-1131]

We further observed that women were more likely to experience greater spreading of pain (i.e., RP-Medium, RP-Heavy, and WSP) than men. This finding is supported by both epidemiological[@b1-jpr-9-1131],[@b12-jpr-9-1131],[@b29-jpr-9-1131],[@b37-jpr-9-1131] and review studies.[@b36-jpr-9-1131],[@b38-jpr-9-1131] Although the exact etiological basis of sex differences regarding pain experience remains unknown, there is evidence supporting that it is due to multiple biological, psychosocial, and cultural variations.[@b36-jpr-9-1131],[@b38-jpr-9-1131] As with some other studies,[@b1-jpr-9-1131],[@b29-jpr-9-1131],[@b34-jpr-9-1131] we found no evidence of an association between age and pain. Despite this lack of evidence, we found peaks for significantly decreased ratios of RP-Heavy in the old old (i.e., 75--84 years old) and oldest old (i.e., ≥85 years old) individuals. Such a decrease in symptomatology might coincide with the idea of fall-off of symptoms with advancing age.[@b50-jpr-9-1131],[@b51-jpr-9-1131] It is reasonable to assume that a certain proportion of the oldest old individuals with severe comorbidities are likely to have passed away at the time of this study. Thus, the survivors might represent a comparatively healthier group where a high prevalence of WSP on the body is less likely to occur.

Not surprisingly, traumatic injuries, rheumatoid arthritis, and osteoarthritis were associated with all pain categories. Regarding the other comorbidities, an association with gastrointestinal disorders was found in LP, RP-Medium, and RP-Heavy. Depressive disorders were associated with all pain categories, except for LP. Disorders of the CNS were associated with the greatest pain spread categories (i.e., RP-Heavy and WSP). These results are consistent with data obtained in cross-sectional and review studies that linked those comorbidities with the development and/or maintenance of WSP.[@b11-jpr-9-1131],[@b16-jpr-9-1131],[@b23-jpr-9-1131],[@b24-jpr-9-1131],[@b27-jpr-9-1131],[@b33-jpr-9-1131],[@b40-jpr-9-1131]--[@b42-jpr-9-1131],[@b52-jpr-9-1131],[@b53-jpr-9-1131] The observed strong relationship between those comorbidities and the pain categories can be partly explained by the fact that greater levels of spreading of pain trigger a tendency in health-seeking behavior more frequently than the more limited spreading of pain.[@b24-jpr-9-1131] Another factor might be that WSP (including fibromyalgia syndrome) is associated with the most prominent central alterations (i.e., central hyperexcitability). The correlation between depressive disorders and the spreading of pain in our study might further be attributed to the fact that older adults seem to be vulnerable to depressive symptoms that often correspond to somatic symptoms as a part of aging.[@b34-jpr-9-1131],[@b51-jpr-9-1131],[@b54-jpr-9-1131]

Our results do not support previous observations of a clear association between the spreading of pain, cancer, and CVDs.[@b24-jpr-9-1131],[@b31-jpr-9-1131],[@b40-jpr-9-1131] This finding is quite intriguing because there is an ongoing discussion in the literature about their relationship.[@b24-jpr-9-1131],[@b31-jpr-9-1131],[@b40-jpr-9-1131] One possible explanation is that our study evaluates the existence of cancer and CVDs in relation to spreading of pain, rather than examining the mortality risk from those disorders related to regional pain and WSP, as other studies focused on.[@b31-jpr-9-1131],[@b40-jpr-9-1131] Unlike our study, these studies did not take into evaluation medication and other comorbidities that might be independently related to pain, cancer, and CVD mortality.[@b31-jpr-9-1131],[@b40-jpr-9-1131],[@b44-jpr-9-1131],[@b47-jpr-9-1131],[@b55-jpr-9-1131] Additionally, some other factors such as smoking may be associated with pain and both cancer and CVD mortality. There is some evidence that pain is associated with smoking behaviors and vice versa,[@b56-jpr-9-1131],[@b57-jpr-9-1131] a habit that contributes to worsening health status, including cancer and CVD morbidity.[@b56-jpr-9-1131] However, in our study nicotine intake was not associated with pain categories. This finding could reflect the fact that our sample had a relatively low prevalence of nicotine intake. These differences can be partly explained by the population studied and the study design; we examined only older adults using a cross-sectional methodology, and this may account for the observed variations regarding cancer, smoking, CVDs, and pain. Nevertheless, these results require more attention and should be tested longitudinally in future studies.

Various medications such as analgesics, hypnotics, and medication for peripheral vascular disorders were independently associated with different pain spread categories. These results seem to support other empirical studies that have shown that the prevalence of pain is associated with polypharmacy.[@b11-jpr-9-1131],[@b58-jpr-9-1131] Notably, WSP had the strongest relationship with analgesics. It appears that older adults with greater pain spread and multi-comorbidity might have a higher prescription of use of such agents. A second explanation can be related to the fact that the medications concern self-reports and that the respondents may have mixed up analgesics and anti-inflammatory medication. Other lifestyle factors (e.g., alcohol intake and physical activity) did not seem to be important factors of spreading of pain in older adults.

Of note, we found that the associations of pain categories with comorbidities and medications were largely reduced when all the comorbidities and medications were simultaneously controlled for ([Table 4](#t4-jpr-9-1131){ref-type="table"}). This finding could imply that the factors associated with spreading of pain in older adults are multifactorial. Even if each one of the examined comorbidities and medications seem to be important factors for spreading of pain, it remains unclear how these factors are combined to affect the experience of pain in this population. These results are important issues for future research.

Study limitations
=================

Due to the cross-sectional study design, interpretations on causal associations between studied variables and different pain categories cannot be confirmed. However, our large sample size provides adequate statistical power to derive concrete interpretations. Another limitation is the use of postal questionnaires and the self-reported measurement of pain as well as the use of other examined variables. Obviously, these methods are generally less precise than a doctor's diagnosis and clinical evaluation.[@b11-jpr-9-1131] Nonetheless, several studies have used analogous approaches to assess the prevalence of pain.[@b6-jpr-9-1131],[@b7-jpr-9-1131],[@b22-jpr-9-1131],[@b24-jpr-9-1131],[@b26-jpr-9-1131],[@b37-jpr-9-1131],[@b40-jpr-9-1131] Finally, we did not examine the role of cognitive function, other socioeconomic factors, or the important interaction between studied variables that might be associated with the pain in older adults.[@b2-jpr-9-1131],[@b11-jpr-9-1131]

Conclusion
==========

This study suggests that older adults with compromised health conditions tend to experience greater spreading of pain. Women appear to be more vulnerable to spreading of pain compared to men. Advancing age per se did not play an important role. Therapeutic plans should take into account these associations to improve pain treatments that inhibit functional deficiency and pain spread-related disability in this population. Given that half of older adults in this study had spreading of pain most often with additional comorbidities under multiple medications, there is an apparent need to further explore the nature of the associations reported here.
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![Distribution of pain categories based on spreading of pain on the body.\
**Abbreviations:** NP, no pain; LP, local pain, RP-Medium, regional pain medium; RP-Heavy, regional pain heavy; WSP, widespread pain.](jpr-9-1131Fig1){#f1-jpr-9-1131}

###### 

Descriptive characteristics of the study in the total sample, in the different pain categories, and comparisons among them.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables (n, %)\            Total sample\   NP (n=3227)    LP (n=1585)    RP-Medium\     RP-Heavy\      WSP (n=114)    Differences among pain categories\
  (otherwise stated)           (n=6611)                                      (n=1344)       (n=341)                       (*p*-value)
  ---------------------------- --------------- -------------- -------------- -------------- -------------- -------------- ------------------------------------
  Sex (n=6611)                                                                                                            **\<0.001**

   Men                         3057 (46.2)     1665 (50.0)    755 (46.3)     519 (37.1)     104 (28.1)     24 (22.2)      

   Women                       3554 (53.8)     1572 (50.0)    830 (53.7)     825 (62.9)     237 (71.9)     90 (77.8)      

  Age strata, years (n=6611)                                                                                              0.209

   65--69                      1488 (31.6)     724 (31.5)     377 (33.3)     292 (30.5)     70 (28.7)      25 (30.4)      

   70--74                      1496 (22.7)     730 (22.8)     341 (21.5)     320 (23.9)     82 (24.2)      23 (20.2)      

   75--79                      1397 (17.4)     655 (16.6)     337 (17.4)     279 (17.2)     90 (21.9)      36 (26.4)      

   80--84                      1251 (13.6)     622 (13.8)     305 (13.7)     258 (14.0)     50 (10.5)      16 (10.6)      

   ≥85                         979 (14.7)      496 (15.3)     225 (14.1)     195 (14.4)     49 (14.7)      14 (12.4)      

  NRS7d (n=3660)                                                                                                          

   Mean (±SD)                  4.3 (±2.4)      0.0 (0.0)      4.3 (±1.9)     5.0 (±1.9)     5.6 (±1.9)     6.0 (±2.3)     **\<0.001**

   Range                       0--10           0--0           1--10          1--10          1--10          1--10          

  Nicotine intake (n=3868)                                                                                                0.892

   Yes                         552 (15.1)      281 (15.5)     129 (14.7)     108 (15.2)     24 (12.9)      10 (13.5)      

   No                          3316 (84.9)     1643 (84.5)    785 (85.3)     643 (84.8)     182 (87.1)     63 (86.5)      

  Alcohol intake (n=6474)                                                                                                 **\<0.001**

   Yes                         4572 (72.0)     2272 (73.3)    1121 (74.0)    908 (70.0)     215 (65.1)     56 (51.0)      

   No                          1902 (28.0)     887 (26.7)     429 (26.0)     412 (30.0)     117 (34.9)     57 (49.0)      

  Physical activity (n=5073)                                                                                              

   Mean (±SD)                  21.5 (±20.9)    22.9 (±21.6)   20.5 (±19.2)   20.3 (±19.8)   19.6 (±19.7)   17.5 (±18.8)   **\<0.001**

   Range                       0--255          0--255         0--158         0--144         0--119         0--90          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** NRS7d, pain intensity for the previous 7 days measured by numeric rating scale. Significant *p*-values are in bold.

**Abbreviations:** NP, no pain; LP, local pain; RP-Medium, regional pain medium; RP-Heavy, regional pain heavy; WSP, widespread pain; SD, standard deviation.

###### 

Prevalence of comorbidities and medications (prescribed and non-prescribed) in the total sample, in the different pain categories, and comparisons among them

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables (n, %)                                Total sample\   NP (n=3227)   LP (n=1585)   RP-Medium\   RP-Heavy\    WSP\        Differences among pain categories\
                                                  (n=6611)                                    (n=1344)     (n=341)      (n=114)     (*p*-value)
  ----------------------------------------------- --------------- ------------- ------------- ------------ ------------ ----------- ------------------------------------
  Comorbidities                                                                                                                     

   Traumatic injuries                             636 (10.8)      158 (5.2)     165(11.6)     215 (19.2)   71 (24.1)    27 (23.1)   **\<0.001**

   Rheumatoid arthritis and osteoarthritis        2165 (37.0)     474 (16.0)    587 (42.4)    772 (66.0)   240 (79.0)   92 (87.8)   **\<0.001**

   Cardiovascular disorders                       3319 (53.8)     1502 (50.0)   791(53.8)     745 (58.8)   209 (66.1)   72 (63.7)   **\<0.001**

   Pulmonary disorders                            879 (14.5)      332 (11.2)    194(13.3)     241 (19.5)   83 (27.8)    29 (27.9)   **\<0.001**

   Depressive disorders                           789 (13.6)      277 (9.5)     196 (13.8)    221 (19.7)   64 (21.8)    31 (31.9)   **\<0.001**

   Anxiety disorders                              995 (16.7)      355 (11.9)    229 (16.0)    279 (23.8)   84 (27.8)    48(47.1)    **\<0.001**

   Gastrointestinal disorders                     1255 (20.9)     363 (12.1)    327 (22.8)    383 (32.0)   132 (42.7)   50 (46.6)   **\<0.001**

   Disorders of CNS                               2524 (39.5)     1040 (33.0)   614 (40.6)    627 (48.0)   180 (55.5)   63 (60.8)   **\<0.001**

   Urogenital disorders                           651 (10.1)      236 (7.4)     167 (11.1)    163 (12.2)   61 (19.2)    24 (22.1)   **\<0.001**

   Skin disorders                                 712 (11.8)      257 (9.3)     185 (12.5)    172 (14.0)   61 (19.9)    19 (19.4)   **\<0.001**

   Tumors and cancer                              505 (8.1)       215 (7.0)     127 (8.5)     116 (9.3)    38 (12.5)    9 (8.6)     **0.007**

   Metabolic disorders                            1059 (17.0)     423 (13.9)    247 (16.2)    270 (21.5)   85 (27.8)    34 (31.8)   **\<0.001**

  Prescribed medication                                                                                                             

   Analgesics                                     1031 (15.7)     149 (4.5)     272 (17.0)    391 (29.4)   149 (44.0)   70 (63.0)   **\<0.001**

   Gastroesophageal reflux medication             537 (8.7)       156 (5.1)     124 (8.2)     178 (14.2)   57 (17.7)    22 (22.4)   **\<0.001**

   Constipation medication                        364 (5.8)       121 (3.9)     75 (4.9)      118 (9.3)    35 (10.7)    15 (13.2)   **\<0.001**

   Hypnotics                                      504 (8.0)       176 (5.8)     122 (7.9)     134 (10.5)   50 (15.3)    22 (20.3)   **\<0.001**

   Anxiolytics                                    333 (5.4)       110 (3.6)     80 (5.4)      98 (7.9)     27 (8.8)     18 (17.0)   **\<0.001**

   Antidepressants                                291 (4.8)       107 (3.7)     68 (4.6)      79 (6.4)     21 (6.8)     16 (15.2)   **\<0.001**

   Anti-inflammatory medication                   442 (7.3)       99 (3.3)      106 (7.1)     144 (11.6)   66 (21.8)    27 (26.3)   **\<0.001**

   Cardiovascular medication                      2015 (31.3)     861 (27.3)    498 (32.5)    481 (36.8)   128 (38.3)   47 (39.7)   **\<0.001**

   Medication for peripheral vascular disorders   645 (10.3)      241 (7.9)     153 (10.2)    183 (14.4)   51 (15.5)    17 (15.1)   **\<0.001**

   Medication for skin disorders                  429 (6.9)       166 (5.4)     103 (6.7)     109 (8.9)    34 (10.6)    17 (15.9)   **\<0.001**

   Insulin agents                                 429 (6.8)       174 (5.7)     104 (6.9)     106 (8.5)    33 (10.3)    12 (10.9)   **\<0.001**

  Non-prescribed medication                                                                                                         

   Analgesics                                     603 (9.4)       65 (2.0)      190 (12.3)    233 (17.6)   80 (23.8)    35 (34.3)   **\<0.001**

   Gastroesophageal reflux medication             259 (4.1)       74 (2.3)      64 (4.0)      87 (6.8)     24 (7.2)     10 (11.0)   **\<0.001**

   Constipation medication                        258 (4.0)       84 (2.7)      58 (3.8)      84 (6.3)     25 (7.6)     7 (6.7)     **\<0.001**

   Anti-inflammatory medication                   166 (2.7)       29 (0.9)      43 (2.8)      60 (4.9)     21 (6.9)     13 (14.9)   **\<0.001**

   Medication for skin disorders                  315 (5.1)       113 (3.7)     74 (4.8)      84 (7.1)     31 (9.0)     13 (13.8)   **\<0.001**

   Asthma medication                              214 (3.5)       69 (2.2)      48 (3.2)      68 (5.5)     22 (7.4)     7 (6.4)     **\<0.001**

   Vitality supplements                           159 (2.7)       57 (2.0)      37 (2.5)      39 (3.2)     21 (7.2)     5 (4.8)     **\<0.001**

   Nutritional deficiencies                       1342 (21.3)     535(17.5)     334 (22.0)    323 (25.3)   112 (34.6)   38 (34.6)   **\<0.001**

   Herbal remedies                                305 (5.1)       91 (3.2)      82 (5.5)      91(7.6)      32 (10.2)    9 (9.8)     **\<0.001**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Significant *p*-values are in bold.

**Abbreviations:** NP, no pain; LP, local pain; RP-Medium, regional pain medium; RP--Heavy, regional pain heavy; WSP, widespread pain; CNS, central nervous system.

###### 

Results of logistic regression analyses: single-predictor models of association of each pain category with sex, age strata, comorbidities, medications, nicotine and alcohol intake, and physical activity

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                       LP, OR\             *p*-Value     RP-Medium, OR (95% CI)   *p*-Value     RP-Heavy, OR (95% CI)   *p*-Value     WSP, OR (95% CI)       *p*-Value
                                                  (95% CI)                                                                                                                              
  ----------------------------------------------- ------------------- ------------- ------------------------ ------------- ----------------------- ------------- ---------------------- -------------
  Women (vs men)                                  1.16 (1.03--1.31)   **\<0.001**   1.69 (1.48--1.92)        **\<0.001**   2.56 (1.99--3.26)       **\<0.001**   3.49 (2.24--5.47)      **\<0.001**

  Age strata, years                                                                                                                                                                     

   70--74 (vs 65--69)                             1.12 (0.91--1.36)   0.280         1.09 (0.92--1.29)        0.341         1.71 (0.86--1.59)       0.313         0.92 (0.54--1.57)      0.762

   75--79 (vs 65--69)                             1.09 (0.88--1.36)   0.401         1.07 (0.88--1.29)        0.509         1.45 (1.05--1.98)       **0.023**     1.64 (0.99--2.71)      0.051

   80--84 (vs 65--69)                             1.14 (0.91--1.42)   0.275         1.05 (0.85--1.28)        0.661         0.83 (0.56--1.24)       0.369         0.88 (0.41--1.54)      0.503

   ≥85 (vs 65--69)                                1.07 (0.83--1.36)   0.583         0.98 (0.81--1.20)        0.553         1.07 (0.75--1.52)       0.730         0.82 (0.45--1.58)      0.601

  Comorbidities (vs no)                                                                                                                                                                 

   Traumatic injuries                             2.38 (1.89--3.00)   **\<0.001**   4.33 (3.47--5.39)        **\<0.001**   5.77 (4.22--7.89)       **\<0.001**   7.41 (4.57--11.97)     **\<0.001**

   Rheumatoid arthritis and osteoarthritis        3.85 (3.31--4.64)   **\<0.001**   10.15 (8.67--11.88)      **\<0.001**   19.07 (14.69--26.28)    **\<0.001**   37.75 (20.85--68.32)   **\<0.001**

   Cardiovascular disorders                       1.16 (1.03--1.32)   **0.018**     1.42 (1.24--1.63)        **\<0.001**   1.94 (1.52--2.49)       **\<0.001**   1.75 (1.18--2.61)      **0.005**

   Pulmonary disorders                            1.21 (1.01--1.47)   **0.046**     1.91 (1.59--2.30)        **\<0.001**   3.05 (2.30--4.03)       **\<0.001**   3.07 (1.95--4.83)      **\<0.001**

   Depressive disorders                           1.52 (1.24--1.85)   **\<0.001**   2.32 (1.91--2.81)        **\<0.001**   2.65 (1.94--3.61)       **\<0.001**   4.44 (2.83--6.97)      **\<0.001**

   Anxiety disorders                              1.41 (1.17--1.68)   **\<0.001**   2.31 (1.93--2.47)        **\<0.001**   2.83 (2.14--3.4)        **\<0.001**   6.55 (4.36--9.85)      **\<0.001**

   Gastrointestinal disorders                     2.14 (1.81--2.53)   **\<0.001**   3.43 (2.91--4.05)        **\<0.001**   5.41 (4.20--6.89)       **\<0.001**   6.36 (4.27--9.46)      **\<0.001**

   Disorders of CNS                               1.39 (1.22--1.58)   **\<0.001**   1.87 (1.63--2.14)        **\<0.001**   2.53 (2.00--3.21)       **\<0.001**   3.15 (2.11--4.69)      **\<0.001**

   Urogenital disorders                           1.56 (1.26--1.95)   **\<0.001**   1.75 (1.28--1.70)        **\<0.001**   2.99 (2.17--4.12)       **\<0.001**   3.56 (2.19--5.79)      **\<0.001**

   Skin disorders                                 1.38 (1.13--1.69)   **0.001**     1.58 (1.29--1.93)        **\<0.001**   2.40 (1.48--2.68)       **\<0.001**   2.33 (1.40--3.88)      **0.001**

   Tumors and cancer                              1.24 (0.98--1.58)   0.072         1.36 (1.06--1.73)        **0.013**     1.19 (1.30--2.79)       **0.001**     1.26 (0.61--2.60)      0.530

   Metabolic disorders                            1.99 (1.01--1.42)   **0.040**     1.69 (1.43--2.01)        **\<0.001**   2.39 (1.83--3.13)       **\<0.001**   2.90 (1.89--4.45)      **\<0.001**

  Prescribed medication (vs no)                                                                                                                                                         

   Analgesics                                     4.32 (3.47--5.37)   **\<0.001**   8.79 (7.12--10.85)       **\<0.001**   16.63 (12.61--21.52)    **\<0.001**   35.98 (23.49--55.11)   **\<0.001**

   Gastroesophageal reflux medication             1.66 (1.29--2.12)   **\<0.001**   3.06 (2.43--3.85)        **\<0.001**   3.96 (2.84--5.15)       **\<0.001**   5.32 (3.26--6.76)      **\<0.001**

   Constipation medication                        1.25 (0.92--1.69)   0.143         2.50 (1.91--3.27)        **\<0.001**   2.93 (1.96--4.39)       **\<0.001**   3.72 (2.05--6.73)      **\<0.001**

   Hypnotics                                      1.39 (1.09--1.77)   **0.007**     1.89 (1.49--2.40)        **\<0.001**   2.92 (2.08--4.12)       **\<0.001**   4.13 (2.51--6.77)      **\<0.001**

   Anxiolytics                                    1.51 (1.13--2.04)   **0.006**     2.28 (1.72--3.03)        **\<0.001**   2.56 (1.66--3.95)       **\<0.001**   5.49 (3.18--9.49)      **\<0.001**

   Antidepressants                                1.23 (0.98--1.72)   0.136         1.79 (1.32--2.39)        **\<0.001**   1.89 (1.17--3.05)       **\<0.001**   4.67 (2.65--8.24)      **\<0.001**

   Anti-inflammatory medication                   2.22 (1.67--2.95)   **\<0.001**   3.78 (2.89--4.39)        **\<0.001**   8.05 (5.76--11.26)      **\<0.001**   10.28 (6.34--16.65)    **\<0.001**

   Cardiovascular medication                      1.28 (1.11--1.47)   **\<0.001**   1.55 (1.34--1.78)        **\<0.001**   1.65 (1.30--2.10)       **\<0.001**   1.75 (1.18--2.59)      **0.005**

   Medication for peripheral vascular disorders   1.32 (1.07--1.65)   **0.011**     1.97 (1.61--2.43)        **\<0.001**   2.14 (1.53--2.99)       **\<0.001**   2.08 (1.19--3.62)      **0.010**

   Medication for skin disorders                  1.25 (0.96--1.62)   0.091         1.69 (1.31--2.17)        **\<0.001**   2.06 (1.39--3.04)       **\<0.001**   3.29 (1.92--5.63)      **\<0.001**

   Insulin agents                                 1.22 (0.95--1.58)   0.115         1.54 (1.19--1.98)        **0.001**     1.99 (1.29--2.85)       **\<0.001**   2.04 (1.08--3.84)      **0.027**

  Non-prescribed medication (vs no)                                                                                                                                                     

   Asthma medication                              1.45 (0.99--2.13)   0.052         2.58(1.82--3.65)         **\<0.001**   3.55 (2.18--5.79)       **\<0.001**   3.04 (1.34--6.91)      **0.008**

   Vitality supplements                           1.26 (0.84--1.92)   0.263         1.63 (1.09--2.45)        **\<0.001**   3.78 (2.30--6.23)       **\<0.001**   2.48 (0.99--6.23)      0.053

   Nutritional deficiencies                       1.33 (1.14--1.55)   **\<0.001**   1.60 (1.36--1.87)        **\<0.001**   2.50 (1.95--3.20)       **\<0.001**   2.51 (1.66--3.78)      **\<0.001**

   Herbal remedies                                1.76 (1.30--2.39)   **\<0.001**   2.47 (1.84--3.31)        **\<0.001**   3.41 (2.25--5.18)       **\<0.001**   3.27 (1.68--6.38)      **0.001**

   Nicotine intake (vs no)                        0.94 (0.75--1.17)   0.597         0.98 (0.77--1.24)        0.883         0.81 (0.53--1.24)       0.335         0.85 (0.43--1.67)      0.645

   Alcohol intake (vs no)                         1.03 (0.90--1.19)   0.598         0.85 (0.73--0.98)        **0.026**     0.68 (0.54--0.87)       **0.002**     0.38 (0.26--0.55)      **\<0.001**

   Physical activity                              0.99 (0.98--0.99)   **0.001**     0.99 (0.98--0.99)        **0.001**     0.99 (0.98 --0.99)      **0.016**     0.98 (0.97--0.99)      **0.021**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Significant *p*-values are in bold.

**Abbreviations:** LP, local pain; OR, odds ratio; CI, confidence interval; RP-Medium, regional pain medium; RP-Heavy, regional pain heavy; WSP, widespread pain; CNS, central nervous system.

###### 

Results of logistic regression analyses: multivariate models of association of each pain category with sex, age strata, comorbidities, medications, alcohol intake, and physical activity

  Variables                                       LP, OR (95% CI)            *p*-Value                  RP-Medium, OR (95% CI)   *p*-Value           RP-Heavy, OR (95% CI)      *p*-Value                  WSP, OR (95% CI)      *p*-Value
  ----------------------------------------------- -------------------------- -------------------------- ------------------------ ------------------- -------------------------- -------------------------- --------------------- -------------
  Women (vs men)                                  1.09 (0.90--1.31)          0.382                      1.15 (1.18--1.94)        **0.001**           2.76 (1.63--4.65)          **\<0.001**                3.80 (1.59--9.07)     **0.003**
  Age strata, years                                                                                                                                                                                                              
   70--74 (vs 65--69)                             Not included (*p*\>0.05)   Not included (*p*\>0.05)   0.87 (0.46--1.65)        0.677               Not included (*p*\>0.05)                                                    
   75--79 (vs 65--69)                             Not included (*p*\>0.05)   Not included (*p*\>0.05)   0.81 (0.41--1.61)        0.557               Not included (*p*\>0.05)                                                    
   80--84 (vs 65--69)                             Not included (*p*\>0.05)   Not included (*p*\>0.05)   0.24 (0.09--0.59)        **0.002**           Not included (*p*\>0.05)                                                    
   ≥85 (vs 65--69)                                Not included (*p*\>0.05)   Not included (*p*\>0.05)   0.23 (0.09--0.55)        **0.001**           Not included (*p*\>0.05)                                                    
  Comorbidities (vs no)                                                                                                                                                                                                          
   Traumatic injuries                             1.89 (1.30--2.66)          **0.001**                  3.29 (2.22--4.89)        **\<0.001**         3.75 (1.96--7.20)          **\<0.001**                5.64 (2.17--14.63)    **\<0.001**
   Rheumatoid arthritis and osteoarthritis        3.78 (3.07--4.66)          **\<0.001**                8.27 (6.46--10.57)       **\<0.001**         10.82 (6.66--17.57)        **\<0.001**                10.02 (4.23--22.68)   **\<0.001**
   Cardiovascular disorders                       1.06 (0.88--1.28)          0.535                      1.13 (0.88--1.44)        0.341               1.12 (0.67--1.86)          0.663                      0.58 (0.26--1.32)     0.198
   Pulmonary disorders                            0.83 (0.61--1.21)          0.224                      1.33 (0.95--1.86)        0.097               1.23 (0.66--2.28)          0.518                      0.75 (0.27--2.10)     0.591
   Depressive disorders                           1.28 (0.94--1.74)          0.110                      1.77 (1.23--2.55)        **0.002**           2.05 (1.08--3.88)          **0.028**                  1.66 (1.23--4.52)     **\<0.001**
   Gastrointestinal disorders                     1.42 (1.15--1.75)          **0.001**                  1.96 (1.50--2.55)        **\<0.001**         2.14 (1.28--3.55)          **0.003**                  1.50 (0.68--3.34)     0.313
   Disorders of CNS                               1.07 (0.88--1.30)          0.514                      1.23 (0.96--1.58)        0.110               1.77 (1.06--2.93)          **0.027**                  2.30 (1.04--5.09)     **0.040**
   Urogenital disorders                           1.19 (0.85--1.66)          0.290                      1.01 (0.64--1.57)        0.998               1.47 (0.66--3.27)          0.335                      1.44 (0.49--4.21)     0.501
   Skin disorders                                 1.02 (0.77--1.35)          0.860                      1.21 (0.86--1.71)        0.266               0.98 (0.51--1.91)          0.965                      1.94 (0.77--4.93)     0.160
   Tumors and cancer                              Not included (*p*\>0.05)   1.19 (0.87--1.45)          0.102                    1.03 (0.45--2.37)   0.948                      Not included (*p*\>0.05)                         
   Metabolic disorders                            0.92 (0.71--1.19)          0.520                      1.33 (0.97--1.82)        0.078               1.31 (0.72--2.35)          0.370                      1.92 (0.80--4.62)     0.142
  Prescribed medication (vs no)                                                                                                                                                                                                  
   Analgesics                                     3.58 (2.69--4.77)          **\<0.001**                6.22 (4.50--8.85)        **\<0.001**         13.95 (8.34--23.35)        **\<0.001**                15.03 (6.81--33.19)   **\<0.001**
   Constipation medication                        Not included (*p*\>0.05)   1.14 (0.67--1.94)          0.621                    1.11 (0.46--2.67)   0.813                      0.87 (0.20--3.82)          0.858                 
   Hypnotics                                      1.25 (0.85--1.85)          0.252                      0.99 (0.59--1.64)        0.962               2.83 (1.33--6.03)          **0.007**                  2.16 (0.65--7.12)     0.204
   Medication for peripheral vascular disorders   1.19 (0.86--1.64)          0.301                      1.52 (1.03--2.26)        **0.036**           1.39 (0.66--2.95)          0.386                      0.95 (0.23--3.16)     0.937
  Non-prescribed medication (vs no)                                                                                                                                                                                              
   Vitality supplements                           Not included (*p*\>0.05)   1.00 (0.45--2.19)          0.999                    2.38 (0.75--1.77)   0.135                      Not included (*p*\>0.05)                         
   Nutritional deficiencies                       0.96 (0.75--1.22)          0.742                      1.23 (0.91--1.66)        0.182               1.44 (0.83--2.51)          0.192                      1.12 (0.49--2.58)     0.783
   Herbal remedies                                1.15 (0.72--1.82)          0.554                      1.43 (0.85--2.40)        0.169               0.95 (0.33--2.69)          0.922                      2.71 (0.77--9.53)     0.120
   Alcohol intake (vs no)                         Not included (*p*\>0.05)   1.25 (0.95--1.65)          0.116                    1.13 (0.65--1.97)   0.660                      0.91 (0.40--2.06)          0.918                 
   Physical activity                              0.99 (0.94--1.01)          0.576                      1.00 (0.99--1.01)        0.940               0.99 (0.98--1.01)          0.864                      1.01 (0.99--1.03)     0.069
  Nagelkerke *R*^2^                               0.184                                                 0.451                                        0.567                                                 0.541                 
  Hosmer and Lemeshow test (*p*-value)            0.058                                                 0.257                                        0.245                                                 0.665                 
  Classification percentage correct               73.0                                                  83.0                                         94.5                                                  97.4                  

**Note:** Significant *p*-values are in bold.

**Abbreviations:** LP, local pain; OR, odds ratio; CI, confidence interval; RP-Medium, regional pain medium; RP-Heavy, regional pain heavy; WSP, widespread pain; CNS, central nervous system.
